Citations 3
Clinical Outcomes of Pre-Transplant Cardiac Prehabilitation in the ICU on Impella 5.5
Jena, Anek , Pareek, Aayushi , Bateh, Said, Faiz, Saleem, Olaizola, Gustavo , Huespe, Ivan, Bauque, Susana, Prado, Eduardo, Hanson, Abby, Sujanyal, Saurabh, Haney, John, Amoroso, Penny, Vilela, Sara, BRITTON, KIMBERLY, Matos, Nikki, Ojard, Michelle, Kiley, Sean, Hannon, Rachel, Moreno, Juan Carlos Leoni, Thomas, Mathew, Sareyyüpoğlu, Başar , Sura, Lydia, Worsowicz, Greg, Lyle, M., Patel, Parag, Sanghavi, Devang, Shapiro, Anna, Bateh, Said , Saleem, Faiz , Prado, Eduardo , Haney, J., Vilela, Sara , Matos, Nikki , Hannon, Rachel, Thomas, Mathew , Worsowicz, Gregory M., Lyle, Melissa , Patel, P S, Franco, Pablo Moreno , Sanghavi, Devang , Shapiro, Anna
ASAIO Journal | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Prehabilitation with Impella 5.5 offers hemodynamic support while allowing early mobilization, yet its overall effect on post-transplant recovery remains unclear. The aim was to assess recovery during Impella 5.5–supported prehabilitation and determine its association with early post-heart transplant outcomes, including a potential dose–response relationship with ambulatory activity. We conducted a single-center retrospective cohort study of adults bridged to transplant with Impella 5.5 between April 1, 2022 and September 30, 2024. Daily walking distance, recorded by nursing staff, served as the intervention. Primary outcome was postoperative hospital length of stay (LOS); the secondary outcome was time to extubation. Fine–Gray competing-risk models, adjusted for age, Sequential Organ Failure Assessment (SOFA) score, New York Heart Association (NYHA) class, and days of Impella support, assessed associations. Longitudinal recovery trajectories were analyzed with linear mixed-effects models incorporating restricted cubic splines. Among 82 eligible patients, 65 met the inclusion criteria. Patients who walked farther during Impella 5.5 support in the intensive care unit (ICU) had shorter hospital stays and were taken off the ventilator sooner after transplantation. The overall recovery peaked during the first 2–3 weeks of support, with smaller recovery thereafter, indicating that most functional recovery occurred early during prehabilitation.
1431: RACE AND SEX DISPARITIES IN MECHANICAL CIRCULATORY SUPPORT USE: NATIONAL INPATIENT SAMPLE 2018-2022
Corro, Rosa, Olanipekun, Titilope, Sujanyal, Saurabh, Jena, Anek , Bateh, Said, Saleem, Faiz, Pathak, Aryan, Patel, Vrutti , Thatigolla, Deeksha, Olaizola, Gustavo , Huespe, Ivan, Hanson, Abby, Desai, Aarti, Moreno, Juan Carlos Leoni, Goswami, R., Lyle, Melissa, Patel, Parag, Sanghavi, Devang, Shapiro, Anna, Olanipekun, Titilope , Bateh, Said , Saleem, Faiz , Lyle, Melissa , Franco, Pablo Moreno , Sanghavi, Devang
Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available
A review of transthyretin cardiac amyloidosis
Leoni, Juan , Chirilă, Răzvan M. , Jhawar, Nikita , Moreno, Juan Carlos Leoni, Chirilă, Răzvan , Leoni, Juan Carlos
Romanian Journal of Internal Medicine | October 21, 2022 | Volume: 61 | Issue: 1 | Pages: 28-34
Abstract Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global longevity is increasing and rates of amyloidosis are also increasing, there is a need to improve diagnostic and therapeutic interventions. Previously, symptom management and transplantation were the mainstay of treatment for heart failure symptoms, but studies using RNAi and siRNA technologies have shifted the paradigm of therapeutic strategy in amyloid cardiomyopathy management. Additionally, early detection and clinical monitoring with numerous imaging and non-imaging techniques are being increasingly investigated. Here, we review the epidemiology, pathophysiology, diagnosis, and management of transthyretin amyloid cardiomyopathy.